Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
May function as suppressor of malignant melanoma. Additionally we are shipping AIM1 Kits (4) and and many more products for this protein.
Showing 4 out of 4 products:
Both DNMT1 (show DNMT1 Antibodies) and AIM1 show maternal allele-specific methylation and paternal allele-specific transcription.
AIM1, ERGIC1 (show ERGIC1 Antibodies), and TPX2 (show TPX2 Antibodies) were shown to be highly expressed especially in prostate cancer tissues, and high mRNA expression of ERGIC1 (show ERGIC1 Antibodies) and TMED3 (show TMED3 Antibodies) associated with AR and ERG (show ERG Antibodies) oncogene (show RAB1A Antibodies) expression
Methylation status of AIM1 in the prostate cancer specimen may predict for time to recurrence in Gleason 3 + 4 = 7 patients undergoing prostatectomy.
AIM1 promoter hypermethylation was found in higher frequency (P = 0.005) in metastatic melanoma (65%) than in primary melanomas (38%).
the structure of AIM1g1, a single betagamma-crystallin domain from the protein absent in melanoma 1, was determined
Absent in melanoma 1 (AIM1), an unusual member of the superfamily , contains 12 betagamma-crystallin motifs in six domains. Some of these motifs diverge considerably from the canonical motif sequence. AIM1g1, the first betagamma-crystallin domain of AIM1.
tumor-promoting effect of deletion in 6q21, that included genes PRDM1 (show PRDM1 Antibodies), ATG5 (show ATG5 Antibodies) and AIM1
May function as suppressor of malignant melanoma. It may exert its effects through interactions with the cytoskeleton.
absent in melanoma 1
, absent in melanoma 1b
, absent in melanoma 1 protein
, beta-gamma crystallin domain containing 1
, beta/gamma crystallin domain-containing protein 1
, suppression of tumorigenicity 4 (malignant melanoma)